Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM versus XIBROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM versus XIBROM.
NAPROXEN SODIUM vs XIBROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
XIBROM (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation.
220-550 mg orally twice daily; maximum 1375 mg/day.
Instill 1 drop into the affected eye(s) 4 times daily starting 24 hours before surgery and continuing for 2 weeks postoperatively.
None Documented
None Documented
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 42 hours. Clinical context: Due to its long half-life, steady-state is achieved after about 8 days of daily dosing, which contributes to sustained anti-inflammatory effect.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Renal: ~70% (primarily as unchanged drug); Biliary/Fecal: ~15% (as metabolites); the remainder is eliminated via other minor pathways.
Category D/X
Category C
NSAID
NSAID